Navigation Links
Hologic Announces Third Quarter Fiscal 2008 Operating Results
Date:7/30/2008

$0.22 per diluted share, in the third quarter of fiscal 2007. Included in the third quarter of fiscal 2008 results were charges relating to the Cytyc merger of $25.1 million attributable to the amortization of intangibles and a restructuring charge of $6.4 million in connection with the resignation of the Company's Executive Chairman in May 2008. Earnings per share information for 2007 have been restated to reflect the Company's 2-for-1 stock split effected on April 2, 2008.

The Company's non-GAAP adjusted net income for the third quarter of fiscal 2008 increased 209% to $84.9 million compared to the Company's non-GAAP adjusted net income of $27.5 million in the third quarter of fiscal 2007. The Company's fiscal 2008 third quarter non-GAAP adjusted net income excludes a $30.6 million charge to operating expenses to amortize the intangible assets acquired from Cytyc, AEG, BioLucent, Fischer, R2 and Suros and the $6.4 million restructuring charge.

Non-GAAP adjusted net income and non-GAAP adjusted EPS are non-GAAP financial measures. A reconciliation of adjusted net income and adjusted EPS to the Company's net income (loss) and EPS for the third quarter and first nine months of fiscal 2008 and 2007 is set forth in the supplemental disclosure schedule attached to this press release. When analyzing the Company's operating performance, investors should not consider these non-GAAP measures as a substitute for net income and EPS prepared in accordance with GAAP.

During the third quarter, Hologic recognized as revenue the sale of 429 Selenia full-field digital mammography systems. At June 28, 2008, the Company's backlog for orders of Selenia systems was 501 systems, including ten orders for Selenia Dimensions tomosynthesis systems for international markets, and total backlog for all products was $378 million.

"While Selenia revenue units were at a record level, revenue dollars fell slightly short of our expectations. This was primarily related t
'/>"/>

SOURCE Hologic, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. Psychological downside to strike action
2. Psychological and Social Issues Associated With Tooth Loss
3. Psychological and social issues associated with tooth loss
4. Hologic, Inc. Announces Grant of Early Termination of Antitrust Waiting Period for Third Wave Technologies, Inc. Tender Offer
5. Hologic to Present at the Jefferies 2nd Annual Healthcare Conference
6. Hologic to Acquire Third Wave Technologies
7. Metformin increases pathologic complete response rates in breast cancer patients with diabetes
8. Hologic to Present at NASDAQs 21st Investor Program in London
9. Hologic Announces Organizational Change
10. Can pathological techniques help identify primary colorectal signet ring cell carcinoma?
11. Electric shocks can cause neurologic and neuropsychological symptoms

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...ers from Virginia Commonwealth University Medical ... oxidation of polyunsaturated fatty acids (PUFA) i...fatty liver (NAFL) to nonalcoholic steatohepatitis...er plasma monounsaturated fatty acids in the blood...pear in the December issue of Hepatology , a jour...
(Date:11/23/2009)... from women,s hair loss for almost ten years, Zsan...ng her progress and the secret behind her success ...of her video diaries which include a direct compar... , (PRWeb UK) November 23,...klosi has released the video diaries that document...
(Date:11/23/2009)...sintheRecommendedPriorityGroups ,, HARRISBURG,P...fHealthannouncedtodaytheywillconductthreeadditiona...Delaware,Lancaster,andLehighcountiesonTuesday,Nov....teredforfreetoindividualsintherecommendedtargetgro...artmentasksthatonlyindividualsinthefollowinggroups...
(Date:11/23/2009)...ls enjoy a pay raise for a job well done. But in s...e performance may actually backfire. , A new ...ings for 25 medical groups across California impro...ide pay-for-performance program in 2004 but not w... , Reporting in the December edition of the Jo...
(Date:11/23/2009)...the agency, said lives could be at risk , ...t from last week,s controversial recommendation th...ing for breast cancer continues, with a former hea...ng women to ignore the guidelines. , "I,m sayin...ly this will increase the number of women dying of...
Breaking Medicine News(10 mins):Health News:Metobolomics uncovers key indicators of nonalcoholic fatty liver disease 2Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 2Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 3Health News:Pennsylvania Department of Health Announces Additional H1N1 Vaccination Clinics in Delaware, Lancaster, Lehigh Counties 2Health News:Medical 'pay for performance' programs help improve care -- but not always, study finds 2Health News:Medical 'pay for performance' programs help improve care -- but not always, study finds 3Health News:Women Should Ignore New Mammogram Guideline, Ex-NIH Chief Says 2Health News:Women Should Ignore New Mammogram Guideline, Ex-NIH Chief Says 3
...pulations at Greatest Risk for Developing End Stag...currently suffer from Kidney Disease, WASHINGTON,...wide coalition of patient advocates, dialysis,prof...e (CKD), today at an educational briefing on Capit...
... A Major Overhaul of Medicare, LEBANON, N.H., Apr... doctors more than the most efficient and effectiv...l people, yet gets worse,results, according to a n...d-standard health care systems such as the Mayo Cl...
...ood vessels that lose their ability to protect the...velopment of amyotrophic lateral sclerosis, better... research published in the April issue of Nature N...e unexpected finding opens up a new front in studi...
...RANCISCO, Calif., April 7, 2008 Hyperion,Therapeu...pany, today,announced that Lota S. Zoth has been e...th formerly served as Senior Vice President and Ch...n/prnh/20070905/AQW076LOGO ), In discussing her a...
... Calif., April 7, 2008 Exponent,Inc. (Nasdaq: EX...ial,results for the first quarter ended March 28, ...t on Monday, April 14, 2008. The Company will host...cer, and Richard Schlenker, Chief Financial Office...
...ce You are Willing to Pay, HUNTINGTON BEACH, Cali...uxury in the best or worst of times. "Make no mist...eir appearance with cosmetic,surgery "says Angela ...ue for the investment they are making in themselve...
Other Medicine News:Health News:Kidney Community Gathers on Capitol Hill to Ask Congress to Support Legislation for Increased Kidney Care Education, Updates for Kidney Dialysis Benefit 2Health News:Kidney Community Gathers on Capitol Hill to Ask Congress to Support Legislation for Increased Kidney Care Education, Updates for Kidney Dialysis Benefit 3Health News:Chronically Ill Patients Get More Care, Less Quality, Says Latest Dartmouth Atlas 2Health News:Chronically Ill Patients Get More Care, Less Quality, Says Latest Dartmouth Atlas 3Health News:Chronically Ill Patients Get More Care, Less Quality, Says Latest Dartmouth Atlas 4Health News:Chronically Ill Patients Get More Care, Less Quality, Says Latest Dartmouth Atlas 5Health News:Chronically Ill Patients Get More Care, Less Quality, Says Latest Dartmouth Atlas 6Health News:Leaky blood vessels open up nerve cells to toxic assault in Lou Gehrig's disease 2Health News:Leaky blood vessels open up nerve cells to toxic assault in Lou Gehrig's disease 3Health News:Leaky blood vessels open up nerve cells to toxic assault in Lou Gehrig's disease 4Health News:Hyperion Therapeutics Elects Lota Zoth to Board of Directors 2Health News:5 Ways to Get the Plastic Surgery That You Want 2
(Date:11/23/2009)..., LASVEGAS,Nov.23/PRNewswire-FirstCall/--CordBlood...rdbloodstemcellpreservationcompany( http://www.cor...potentialofstemcells,abiologicalinsurancepolicy,to...ythatanupdatedprogressinterviewwithCEOandco-founde...terviewisat: http://blip.tv/file/2875811 . ,, I...
(Date:11/23/2009)..., PRINCETON,N.J.,Nov.23/PRNewswire-FirstCall/--Pha...rollmentofCohort2,ledbyitspartnerRoche(SWX:ROG.VX;...notype1and4patientsintheongoingphase2btrialofRG712...orforthetreatmentofchronichepatitisCvirus(HCV)infe...anindependentDataMonitoringCommittee(DMC)ofallavai...
(Date:11/23/2009)..., NOVATO,Calif.,Nov.23/PRNewswire-FirstCall/--Rapt...aq: RPTP ),todayannouncedresultsfromaPhase2bclinic...tartrate("DRCysteamine")inpatientswithnephropathic...iversityofCalifornia,SanDiego("UCSD")GeneralClinic...macokineticsandpharmacodynamicsofasingledoseofDRCy...
Breaking Medicine Technology:Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 2Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 3Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 4Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 2Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 3Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 4Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 5BioMarin to Host Second Quarter 2009 Financial Results Conference Call and Webcast on Thursday July 30 at 5 3A00 p m ET 2823 3A00 CET 29 50515 1BioMarin to Host Second Quarter 2009 Financial Results Conference Call and Webcast on Thursday July 30 at 5 3A00 p m ET 2823 3A00 CET 29 50515 2Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 1Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 2Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 3Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 4Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 5Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 6Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 7Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 8Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 9Antibiotics May Boost Risk for Recurrent Ear Infection 50511 1Antibiotics May Boost Risk for Recurrent Ear Infection 50511 2
...SNO, Calif., Oct. 29 Cypress Systems, Inc., a Fre...t the SELECT TRIAL results --,that were announced ...nomethionine. The SELECT TRIAL found no effects of...ence of prostate cancer. See,Related Website at h...LECT TRIAL are consistent with previous animal,stu...
...ANSE is the first oral ADHD stimulant medication w...t 13 hours post-dose in a pediatric clinical,study...SHPGY), the global specialty biopharmaceutical com...g classroom study in school-aged children aged,6 t...sorder (ADHD). In this,study, researchers found th...
Other Medicine Technology:SELECT TRIAL Used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R) - Previous Research has Shown SelenoExcell(R) Supplementation to Reduce Lung, Colon and Prostate Cancers by as Much as 63%, Says Cypress Systems, Inc. 2Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD 2Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD 3Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD 4Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD 5Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD 6Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD 7
Spinchron 15 Refrigerated Centrifuge
Adams Compact II
Dynac III
Rotanta 460
Medicine Products: